Beta-adrenergic antagonists in the treatment of glaucoma.
Beta-blockers have been used since the late 1970's as 'first-choice' in the treatment for glaucoma. Since the introduction of new molecules in clinical routine, the current role of beta-blockers in glaucoma therapy has been rediscussed. In particular, concerns have been raised regarding their actual safety profile. This review will focus on the latest advances on the efficacy and safety profiles of non-selective beta-blockers. The data provided will help to trace a more appropriate role for beta-blockers in glaucoma therapy.